Tempus AI (NASDAQ:TEM) Trading Up 5.2% – Still a Buy?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price was up 5.2% on Friday . The company traded as high as $91.45 and last traded at $88.11. Approximately 13,619,652 shares changed hands during trading, an increase of 2% from the average daily volume of 13,370,095 shares. The stock had previously closed at $83.75.

Analysts Set New Price Targets

TEM has been the subject of several research reports. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. William Blair lowered Tempus AI from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Wolfe Research started coverage on Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Loop Capital decreased their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Price Performance

The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The business’s 50-day simple moving average is $46.60 and its two-hundred day simple moving average is $50.32.

Insider Activity

In related news, Director Jennifer A. Doudna sold 1,320 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $90.00, for a total transaction of $118,800.00. Following the sale, the director now directly owns 36,011 shares of the company’s stock, valued at approximately $3,240,990. This represents a 3.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 2,401,779 shares of company stock worth $115,707,361.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently made changes to their positions in the stock. Kovitz Investment Group Partners LLC bought a new stake in Tempus AI in the 3rd quarter valued at about $1,367,000. China Universal Asset Management Co. Ltd. acquired a new stake in Tempus AI during the fourth quarter valued at approximately $1,091,000. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after acquiring an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of Tempus AI during the third quarter worth $2,726,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Tempus AI in the 4th quarter valued at $178,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.